Effect of aspirin on phase gradient of 2F1-F2 distortion product otoacoustic emissions.
It is well known that aspirin consumption temporarily reduces overall otoacoustic emission (OAE) amplitude in humans. However, little is known about changes in the separate components of distortion product otoacoustic emissions (DPOAE), which may be distinguished by examining phase gradients. The effects of aspirin on the phase gradient of the DPOAE 2F1-F2 obtained with fixed frequency ratio sweeps were studied longitudinally in a group of twelve subjects in whom a temporary hearing loss was induced by aspirin consumption. DPOAE were recorded daily for two days pre-aspirin consumption, during the three days of aspirin consumption and two days afterwards. DP-grams were recorded over a restricted frequency range centered on 2,3,4 and 6 kHz with the following stimulus levels: L1/L2 of 60/50-80/70 in 10-dB steps. The effects of aspirin on the phase gradients varied between the subjects and across frequency: the general trend was that the phase gradient became steeper across successive sessions for the higher frequencies, while no significant effect was found at the lower frequencies. These results suggest that aspirin may have more persistent effects on cochlear function than are disclosed by measurements of hearing threshold level or DPOAE amplitude. Particularly, DPOAE phase gradient appears to be increased by aspirin consumption and has not recovered two days after cessation of aspirin intake, despite almost complete recovery of DPOAE amplitude and hearing threshold levels. These findings may suggest differential effects on the distortion and reflection mechanisms considered to underlie DPOAE generation.
Parazzini
M
M
Istituto di Ingegneria Biomedica ISIB, CNR, Milan, Piazza Leonardo da Vinci 32, 20133 Milano, Italy. marta.parazzini@polimit.it
Hall
A J
AJ
Lutman
M E
ME
Kapadia
S
S
D000161:Acoustic Stimulation; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000097:blood / Q000494:pharmacology*; D001241:Aspirin / Q000097:blood / Q000494:pharmacology*; D003051:Cochlea / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D018072:Hair Cells, Auditory, Outer / Q000187:drug effects; D034381:Hearing Loss / Q000139:chemically induced; D006801:Humans; D008297:Male; D017084:Otoacoustic Emissions, Spontaneous / Q000187:drug effects* / Q000502:physiology; D011930:Reaction Time
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin